You can buy or sell NTLA and other stocks, options, ETFs, and crypto commission-free!
Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. Read More The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
52 Week High
52 Week Low
Yahoo FinanceMay 9
Is Intellia Therapeutics, Inc. A Good Stock To Buy?
"October lived up to its scary reputation—the S&P 500 falling in the month by the largest amount in the last 40 years, the only worse Octobers being '08 and the Crash of '87. For perspective, there have been only 5 occasions in those 40 years when the S&P 500 declined by greater than 20% from peak to trough.
Simply Wall StMay 4
Need To Know: Intellia Therapeutics, Inc. (NASDAQ:NTLA) Insiders Have Been Buying Shares
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders have sold shares. So before you buy or sell Intellia Therapeutics, Inc. (NASDAQ:NTLA), you may well want to know whether insiders have been buying or selling. What Is Insider Selling? Most in...
Expected Jul 31, Pre-Market